This is the authors' abstract. We don't add key points for this paper.
N-glycosylation is one of the most common post-translational modifications and it contributes to proper folding and function of proteins. Class B1 G protein-coupled receptors (GPCRs) are the receptors for peptide hormones that control various body functions and regulate homeostasis. These receptors have a relatively large extracellular domain (ECD) where at least one N-glycosylation site is present. N-glycosylation was reported to enhance pharmacodynamic properties of these receptors such as receptor-ligand binding and receptor activation potency. Here, we summarized N-glycosylation effects of these receptors focusing on cell-surface receptor expression, ligand binding affinity, and receptor activation potency. Receptor N-glycosylation exemplified with calcitonin and amylin receptors apparently enhanced the binding affinity of peptide ligands. Critical N-glycosites that drive whole N-glycosylation effects were reported in the receptors for calcitonin, amylin, calcitonin gene-related peptide, glucose-dependent insulinotropic polypeptide and secretin. In contrast, glucagon-like peptide-1 and corticotropin-releasing factor 1 receptors appear to have each-N-glycosite collectively contribute to the whole-N-glycosylation effects. The potential mechanism of how N-glycosylation enhances the peptide ligand affinity was also addressed. Although there are unexplored receptors that need investigation, N-glycosylation is critical for most of class B1 GPCRs to elicit their normal receptor function. Drug development targeting these receptors should consider the N-glycosylation effects on peptide ligand affinity and receptor activation potency for the accurate evaluation of drug-receptor interaction.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: